# Anterios

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anterios

- Industry: Pharmaceuticals
- Headquarters: New York, US
- Website: www.anteriosinc.com
- Total disclosed funding: $17M
- Latest round: Series B (Mar 25, 2013)
- Investors on record: 3

## About

Anterios is a biotechnology firm focused on developing innovative treatments for complex diseases, leveraging advanced technology to improve patient outcomes through its specialized products and services.Anterios, founded in 2006 and headquartered in New York, US, is a biotechnology company that specializes in developing treatments for complex medical conditions. The firm has undergone a significant transition, being acquired by Allergan Inc. in January 2016 for USD 90.00 mn. The acquisition marked a pivotal moment in the company's evolution, allowing for enhanced resources and research capabilities. Anterios has been involved in a total of 8 deals, reflecting its active engagement in the biotechnology sector. Information regarding the founder or CEO is currently not available.Anterios is dedicated to the development of innovative biopharmaceutical solutions for complex diseases. Its product portfolio includes biologics and therapies targeting conditions such as rheumatoid arthritis and various forms of cancer, focusing on enhancing patient outcomes through advanced therapeutic interventions. The company’s products are positioned for healthcare providers and specialty pharmacies, aiming to meet the needs of patients requiring specialized treatments.Anterios generates revenue primarily through the sale of its biotechnology products, which are marketed to healthcare providers and specialty pharmacies. The pricing for these products is based on negotiated contracts reflecting the therapeutic value provided to patients. Revenue streams are bolstered by the company's core offerings, which target significant therapeutic needs, contributing to its financial sustainability.Following its acquisition by Allergan in January 2016, Anterios plans to utilize the recent funding of USD 90.00 mn to expedite the development of new biopharmaceutical products and expand its market presence. The company aims to launch new therapies targeting additional complex diseases in the coming years, with plans to enter international markets in Europe and Asia-Pacific by 2024, enhancing its global reach and accessibility.

## Funding rounds

- Series B, Mar 25, 2013, $4.7M — Ascent Biomedical Ventures, Scientific Health Development
- Series B, Oct 21, 2009, $5.2M — Ascent Biomedical Ventures, Quantum Technology Partners, Scientific Health Development
- Series A, Jan 26, 2007, $7.5M — Ascent Biomedical Ventures

## Investors

- Ascent Biomedical Ventures (https://capitalatlas.ai/funds/ascent-biomedical-ventures) — Series A, Series B
- Quantum Technology Partners (https://capitalatlas.ai/funds/quantum-technology-partners) — Series B
- Scientific Health Development (https://capitalatlas.ai/funds/scientific-health-development) — Series B